Lehigh Valley Health Network (LVHN) it the first in Pennsylvania to offer a noninvasive, state-of-the-art prostate cancer treatment that precisely targets the disease with a low risk for complications or side effects.
The Focal One system uses robotic-assisted high-intensity focused ultrasound to attack cancerous growths, while sparing the rest of the organ.
The incidence of prostate cancer grew 3 percent each year from 2014 to 2019, reversing a period of decline, according to urologist Angelo Baccala, MD, Chief, Division of Urology, LVHN. Pennsylvania is in the top five states for prostate cancer, and 288,000 cases are predicted in the U.S. this year.
Focal One may be an appropriate treatment option for these individuals, depending on the location and quantity of the cancer